Novo CEO signals M&A opportunities to strengthen drug pipeline
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Read the full article on CNBC
Read Full Article →